CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
Rhea-AI Summary
CytoSorbents (NASDAQ: CTSO), a leader in blood purification technology for treating life-threatening conditions in intensive care and cardiac surgery, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York, NY.
Key points:
- CEO Dr. Phillip Chan and CFO Peter J. Mariani will attend and present
- On-demand company presentation available from September 9 at 7:00 AM ET
- Management team available for one-on-one meetings on September 9
- Presentation replay will be accessible on CytoSorbents's website for 90 days
This conference provides an opportunity for CytoSorbents to showcase its innovative blood purification technology to potential investors and industry professionals.
Positive
- None.
Negative
- None.
News Market Reaction – CTSO
On the day this news was published, CTSO declined 2.80%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that the Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY.
A company presentation will be available on demand here as of Monday, September 9 at 7:00 AM ET. CytoSorbents’ management team will be available for one-on-one meetings Monday, September 9, 2024. Interested investors should contact their representative at H.C. Wainwright. A replay of the presentation will be posted, when available, to CytoSorbents’s website on the Events & Presentation page of the investors section for 90 days.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 76 countries worldwide. It is an extracorporeal cytokine adsorber that reduces “cytokine storm” or “cytokine release syndrome” in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure. As of June 30, 2024, more than 248,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved in the United States.
The DrugSorb™-ATR antithrombotic removal system, an investigational device based on the same polymer technology as CytoSorb, has received two FDA Breakthrough Device Designations, one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. The Company has completed the FDA-approved, randomized, controlled STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) study of 140 patients at approximately 30 centers in U.S. and Canada to evaluate whether intraoperative use of DrugSorb-ATR can reduce the perioperative risk of bleeding in patients receiving ticagrelor and undergoing cardiothoracic surgery. This pivotal study is intended to support U.S. FDA and Health Canada marketing approval for DrugSorb-ATR in this application.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately
Please Click to Follow Us on Facebook and X
Company Contact:
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
pmariani@cytosorbents.com
Investor Relations Contact:
Eric Ribner
LifeSci Advisors, LLC
250 W 55th St, #3401
New York, NY 10019
+1 (646) 751-4363
ir@cytosorbents.com
FAQ
When is CytoSorbents (CTSO) presenting at the H.C. Wainwright Global Investment Conference?
Where is the H.C. Wainwright Global Investment Conference being held in 2024?
Who will be representing CytoSorbents (CTSO) at the 2024 H.C. Wainwright conference?
How long will CytoSorbents' (CTSO) presentation be available for replay after the conference?
